Zymeworks Return on Tangible Equity 2016-2022 | ZYME
Current and historical return on tangible equity values for Zymeworks (ZYME) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Zymeworks Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-06-30 |
$-0.24B |
$0.20B |
-98.45% |
| 2022-03-31 |
$-0.24B |
$0.27B |
-90.18% |
| 2021-12-31 |
$-0.21B |
$0.23B |
-73.20% |
| 2021-09-30 |
$-0.21B |
$0.26B |
-64.05% |
| 2021-06-30 |
$-0.22B |
$0.31B |
-60.79% |
| 2021-03-31 |
$-0.20B |
$0.36B |
-47.56% |
| 2020-12-31 |
$-0.18B |
$0.39B |
-40.58% |
| 2020-09-30 |
$-0.22B |
$0.41B |
-53.12% |
| 2020-06-30 |
$-0.17B |
$0.47B |
-45.99% |
| 2020-03-31 |
$-0.16B |
$0.51B |
-48.14% |
| 2019-12-31 |
$-0.15B |
$0.23B |
-58.12% |
| 2019-09-30 |
$-0.06B |
$0.29B |
-27.32% |
| 2019-06-30 |
$-0.05B |
$0.32B |
-26.47% |
| 2019-03-31 |
$-0.03B |
$0.16B |
-18.38% |
| 2018-12-31 |
$-0.04B |
$0.17B |
-25.61% |
| 2018-09-30 |
$-0.01B |
$0.16B |
-10.10% |
| 2018-06-30 |
$-0.01B |
$0.17B |
-9.30% |
| 2018-03-31 |
$-0.02B |
$0.08B |
-17.60% |
| 2017-12-31 |
$-0.01B |
$0.10B |
-13.51% |
| 2017-09-30 |
$-0.05B |
$0.07B |
-87.45% |
| 2017-06-30 |
$-0.05B |
$0.09B |
-112.99% |
| 2017-03-31 |
$-0.05B |
$0.04B |
-200.00% |
| 2016-12-31 |
$-0.03B |
$0.06B |
-240.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.570B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
